OncologyONC-007Publishedv1.0.0

Pediatric Oncology Strategy Pack

Navigate pediatric oncology requirements with regulatory clarity

~30s runtime3 evidence sources3 regulatory mappingsUpdated Dec 2025

Summary

Synthesizes RACE Act requirements, FDA pediatric study plans, and pediatric trial outcomes to support pediatric oncology development strategies.

Detailed Description

The Pediatric Oncology Strategy Pack addresses the complex regulatory landscape for pediatric oncology drug development, including the Research to Accelerate Cures and Equity (RACE) for Children Act and Pediatric Research Equity Act (PREA) requirements. It compiles FDA pediatric guidance, the Pediatric Study Plan (PSP) database, and published pediatric oncology trial outcomes.

The pack evaluates your molecular target against the FDA's pediatric molecular target list to determine RACE Act applicability and maps the required pediatric study plan components. It analyzes precedent PSPs and pediatric oncology approvals to identify successful development strategies and common regulatory pitfalls.

Deliverables include a RACE Act applicability assessment, a pediatric study plan template pre-populated with precedent-based recommendations, and a pediatric oncology development timeline aligned with adult program milestones.

Evidence Sources

SourceTypeDescriptionRefresh
FDA Pediatric Oncology GuidanceREGULATORYFDA guidance on RACE Act, PREA requirements, and pediatric oncology drug developmentMonthly
Pediatric Study Plan DatabaseREGULATORYFDA database of submitted and agreed-upon pediatric study plans for oncology productsQuarterly
Pediatric Trial OutcomesREGISTRYPublished results and regulatory outcomes from pediatric oncology clinical trialsWeekly

Regulatory Mapping

FDARACE for Children Act

Research to Accelerate Cures and Equity for Children Act

PRIMARY
FDAPREA

Pediatric Research Equity Act

PRIMARY
FDAFDA-2020-D-0957

Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans

PRIMARY

Agent Transparency

When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.

🔍

Evidence Retriever

brew-retriever-v3

Step 1

Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.

Confidence floor: 85%Avg latency: 4-8s
🧬

Domain Analyzer

brew-domain-analyst-v2

Step 2

Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.

Confidence floor: 80%Avg latency: 6-12s
📊

Evidence Synthesizer

brew-synthesizer-v2

Step 3

Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.

Confidence floor: 82%Avg latency: 8-15s

Output Validator

brew-validator-v1

Step 4

Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.

Confidence floor: 90%Avg latency: 2-4s

Sample Outputs

RACE Act Applicability Assessment

PDF

Assessment of RACE Act obligations based on molecular target analysis and FDA pediatric target list

Pediatric Study Plan Template

DOCX

Pre-populated PSP template with precedent-based recommendations for study design and endpoints

Pediatric Development Timeline

XLSX

Integrated timeline aligning pediatric development milestones with adult program

Deliverables included

  • RACE Act applicability and obligation assessment
  • Pediatric Study Plan template with precedent analysis
  • Pediatric development timeline and milestone plan
  • Pediatric formulation development considerations
  • Extrapolation strategy assessment

Related Disease & Biomarker Mappings

Therapeutic AreaDisease FamilyKey BiomarkersRelevance
Solid TumorsNon-Small Cell Lung Cancer
EGFRALKPD-L1KRAS G12C
Primary
Solid TumorsBreast Cancer
HER2ER/PRBRCA1/2PIK3CA
Primary
Hematologic MalignanciesAcute Myeloid Leukemia
FLT3-ITDIDH1/2NPM1
Secondary
Solid TumorsColorectal Cancer
KRAS/NRASBRAF V600EMSI-H/dMMR
Secondary

Related Packs in Oncology

Version History

v1.0.0CurrentNovember 14, 2025

Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.

v0.9.0October 15, 2025

Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.

v0.1.0September 15, 2025

Initial draft — core evidence retrieval pipeline and output schema established.

Need a Custom Evidence Pack?

Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.

Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.